Loading institutional data...
Loading institutional data...
Held by 750 of 5,944 reporting institutions (98th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 40%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest.
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $245.51 today, the market must believe free cash flow compounds 32.7%/yr for a decade (off $254M normalized FCF).
The market's 32.7% is more conservative than its 2-yr track record.
2-stage DCF · 0.13B shares · net debt -$1.7B
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
5/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on $465M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.71B 100.0% | $2.25B 100.0% | $1.83B 100.0% | $1.04B 100.0% | $844.3M 100.0% | $492.9M 100.0% | $219.8M 100.0% | $74.9M 100.0% | $89.9M 100.0% | $47.2M 100.0% |
| Cost of Revenue | $677.2M 18.2% | $306.5M 13.6% | $268.2M 14.7% | $140.2M 13.5% | $115.0M 13.6% | $74.2M 15.1% | $25.1M 11.4% | $1.8M 2.4% | $0 0.0% | — |
| Research & Development | $1.32B 35.5% | $1.13B 50.1% | $1.00B 54.9% | $883.0M 85.1% | $792.2M 93.8% | $654.8M 132.9% | $655.1M 298.1% | $505.4M 674.7% | $390.6M 434.5% | $382.4M 810.9% |
| Selling, General & Admin | $1.21B 32.6% | $975.5M 43.4% | $795.6M 43.5% | $770.7M 74.3% | $620.6M 73.5% | $588.4M 119.4% | $479.0M 218.0% | $382.4M 510.4% | $199.4M 221.7% | $89.4M 189.5% |
| Total Operating Expenses | $3.21B 86.5% | $2.43B 107.9% | $2.11B 115.4% | $1.82B 175.7% | $1.55B 183.9% | $1.32B 268.1% | $1.16B 527.5% | $889.6M 1187.6% | $590.0M 656.2% | $471.7M 1000.3% |
| Operating Income | $501.6M 13.5% | -$176.9M -7.9% | -$282.2M -15.4% | -$785.1M -75.7% | -$708.7M -83.9% | -$828.4M -168.1% | -$939.4M -427.5% | -$814.7M -1087.6% | -$500.1M -556.2% | -$424.6M -900.3% |
| Interest Expense | $252.6M 6.8% | $141.9M 6.3% | $121.2M 6.6% | $156.0M 15.0% | $143.0M 16.9% | $84.5M 17.1% | $0 0.0% | $0 0.0% | — | — |
| Interest & Investment Income | $111.5M 3.0% | $122.0M 5.4% | $95.6M 5.2% | $24.8M 2.4% | $1.6M 0.2% | $11.8M 2.4% | $33.4M 15.2% | $29.3M 39.1% | — | — |
| Other Income (Expense), net | -$178.4M -4.8% | -$200.5M -8.9% | -$151.3M -8.3% | -$341.9M -33.0% | -$143.5M -17.0% | -$27.2M -5.5% | $54.2M 24.7% | $54.0M 72.1% | $9.2M 10.2% | $14.5M 30.7% |
| Pretax Income | $323.2M 8.7% | -$377.4M -16.8% | -$433.5M -23.7% | -$1.13B -108.6% | -$852.1M -100.9% | -$855.6M -173.6% | -$885.3M -402.8% | -$760.7M -1015.5% | -$490.9M -545.9% | -$410.1M -869.6% |
| Income Tax Expense | $9.4M 0.3% | -$99.2M -4.4% | $6.7M 0.4% | $4.2M 0.4% | $680K 0.1% | $2.7M 0.5% | $863K 0.4% | $823K 1.1% | $0 0.0% | $0 0.0% |
| Net Income | $313.7M 8.4% | -$278.2M -12.4% | -$440.2M -24.1% | -$1.13B -109.0% | -$852.8M -101.0% | -$858.3M -174.1% | -$886.1M -403.2% | -$761.5M -1016.6% | -$490.9M -545.9% | -$410.1M -869.6% |
| Per Share | ||||||||||
| EPS (Basic) | $2.39 | $-2.18 | $-3.52 | $-9.30 | $-7.20 | $-7.46 | $-8.11 | — | — | — |
| EPS (Diluted) | $2.33 | $-2.18 | $-3.52 | $-9.30 | $-7.20 | $-7.46 | $-8.11 | — | — | — |
| Weighted Avg Shares (Basic) | 131.0M | 127.7M | 124.9M | 121.7M | 118.5M | 115.0M | 109.3M | — | — | — |
| Weighted Avg Shares (Diluted) | 134.7M | 127.7M | 124.9M | 121.7M | 118.5M | 115.0M | 109.3M | — | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-09-17
No material risks flagged.
Where each multiple sits in its own 14-yr range · 42th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 2.4 | 11.4 | 15.1 | 13.6 | 13.5 | 14.7 | 13.6 | 18.2 |
| R&D | 674.7 | 298.1 | 132.9 | 93.8 | 85.1 | 54.9 | 50.1 | 35.5 |
| SG&A | 510.4 | 218.0 | 119.4 | 73.5 | 74.3 | 43.5 | 43.4 | 32.6 |
| Operating Income | -1087.6 | -427.5 | -168.1 | -83.9 | -75.7 | -15.4 | -7.9 | 13.5 |
| Income Tax | 1.1 | 0.4 | 0.5 | 0.1 | 0.4 | 0.4 | -4.4 | 0.3 |
| Net Income | -1016.6 | -403.2 | -174.1 | -101.0 | -109.0 | -24.1 | -12.4 | 8.4 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on ALNY: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| ALNY | $32.5B | 105.4× | 55.4× | 8.8× | 65.2% | 81.8% | 8.4% | 39.8% | 39.8% | — | 750 |
Peers = companies sharing ALNY's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.